Considerations for non-clinical safety studies of therapeutic peptide vaccines

Abstract

Guidelines for non-clinical studies of prophylactic vaccines against infectious diseases have been published widely, but similar guidelines for therapeutic vaccines, and especially therapeutic peptide vaccines, have yet to be established. The approach to non-clinical safety studies required for therapeutic vaccines differs from that for prophylactic vaccines due to differences in the risk-benefit balance and the mechanisms of action. We propose the following guidelines for non-clinical safety studies for therapeutic peptide vaccines. (i) Since the main safety concern is related to the immune response that might occur at normal sites that express a target antigen, identification of these possible target sites using in silico human expression data is important. (ii) Due to the strong dependence on HLA, it is not feasible to replicate immune responses in animals. Thus, the required non-clinical safety studies are characterized as those detecting off-target toxicity rather than on-target toxicity.

Keywords: Cellular immunity; Cytotoxic T-cells (CTLs); Guidelines; Human leukocyte antigen (HLA); Non-clinical safety study; Off-target toxicity; On-target toxicity; Prophylactic vaccines against infectious diseases; Therapeutic peptide vaccines.